Q32 Bio Inc.
QTTB - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$126.44M
Close$
$3.99
55.5% downside
Current Fair Value
55.5% downsideOvervalued by 55.5% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $126.44 Million |
|---|---|
| Enterprise Value | $24.73 Million |
| Earnings per Share | $2.42 |
| Beta | -0.33 |
| Outstanding Shares | 14,095,371 |
Return
| Return on Equity | 31.90% |
|---|---|
| Return on Assets | 29.16% |
| Return on Invested Capital | 19.67% |
Valuation & Multiples
| P/E Ratio | 3.19 |
|---|---|
| PEG | -55.81 |
| Price to Sales | 2.99 |
| Price to Book Ratio | 1.28 |
| Enterprise Value to Revenue | 0.46 |
| Enterprise Value to EBIT | 1.14 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0.18 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$-0.53
Consensus analyst estimateRevenue Estimate
$1.00 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.36
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 157.35% |
|---|---|
| Total Invested | $579▼ 100.00% |
| Investors Holding | 1▼ 72.00% |
About Q32 Bio Inc.
131 employees
CEO: Arthur Tzianabos
homology medicines is a genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases.